适温响应纳米催化剂用于控制药物释放和增强的催化疗法
Mengmeng Xu1, Xiaoqi Xie1, Yuan Liu1
1South China Advanced Institute for Soft Matter Science and Technology, School of Emergent Soft Matter, Guangdong Provincial Key Laboratory of Functional and Intelligent Hybrid Materials and Devices, South China University of Technology, Guangzhou 510640, PR China.
Acta biomaterialia
|June 4, 2023
概括
这项研究引入了一种新的纳米催化剂,通过在现场产生有毒物质来增强癌症治疗. 该纳米平台放大过氧化 (H2O2),并利用温和的光热疗法改善瘤治疗.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 癌症治疗方法 癌症治疗方法
背景情况:
- 纳米催化疗法通过催化产生有毒物质,显示出对癌症治疗的前景.
- 瘤中有限的内源性过氧化 (H2O2) 限制了纳米催化剂的有效性.
- 碳囊纳米粒子 (CV NPs) 提供高效的近红外 (NIR) 光热转换.
研究的目的:
- 开发一个用于增强癌症治疗的多功能纳米平台.
- 为了克服瘤微环境中低H2O2水平的限制.
- 将光热疗法与纳米催化疗法相结合,以获得协同效应.
主要方法:
- 用铁合金纳米粒子 (PtFe NP) 装载的碳囊纳米粒子 (CV NP) 的制造.
- 在多孔CV@PtFeNP中封装β-lapachone (La) 药物和相变材料 (PCM).
- 在现场产生有毒剂 (基) 和受控的药物释放,由NIR光触发.
主要成果:
- CV@PtFe/(La-PCM) NP显示了NIR触发的光热效应,并激活了热冲击反应,上调了NQO1.
- 纳米平台提供氧气 (O2),以增强H2O2生成,并促进基于PtFe的纳米催化.
- 观察到H2O2有效地分解成有毒的基基 (•OH),用于催化疗法.
- 在体外和体内研究证实了多功能纳米催化剂的强有力的抗瘤作用.
结论:
- 开发的多功能纳米催化剂 (CV@PtFe/(La-PCM) NPs) 为协同治疗癌症提供了一个有前途的战略.
- 与轻度光热疗法相结合的NIR增强纳米催化疗法显示出针对性癌症治疗的显著潜力.
- 这种方法有效地放大瘤特定的H2O2产量,并提高治疗结果,减少对正常组织的损伤.
相关概念视频
01:20Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...